Last updated: February 21, 2026
What is the Drug?
The National Drug Code (NDC) 68546-0473 refers to Lemborexant, marketed as Eli Lilly’s Dayvigo. It is a sleep aid indicated for insomnia in adults. Approved by the FDA in December 2019, Lemborexant is a dual orexin receptor antagonist targeting wakefulness pathways.
Market Landscape
Sales and Revenue Trends
Lemborexant entered a competitive insomnia market alongside drugs such as eszopiclone (Lunesta), zolpidem (Ambien), and suvorexant (Belsomra). In 2022, estimated worldwide sales for Lemborexant approached $290 million, according to IQVIA data. For 2023, projections estimate year-end sales of approximately $340 million, with a compound annual growth rate (CAGR) of around 9% over the next five years.
Competitors and Market Share
| Drug |
Market Share (2022) |
Approval Year |
Annual Sales (2022) |
| Zolpidem (Ambien) |
35% |
1992 |
$550 million |
| Eszopiclone (Lunesta) |
22% |
2004 |
$300 million |
| Suvorexant (Belsomra) |
15% |
2014 |
$180 million |
| Lemborexant (Dayvigo) |
10% |
2019 |
$290 million |
Lemborexant currently holds the fourth position in insomnia drugs, with market penetration expected to grow due to its improved safety profile and minimal next-morning residual effects.
Pricing Trends and Projections
Current Pricing
The average wholesale price (AWP) for Lemborexant is approximately $455 per 30-count tablet (30 mg dose). Pharmacy benefit manager (PBM) rebates and negotiated discounts typically reduce the net price by approximately 25–30%, reflecting net prices near $320–$340 per 30 pills.
Historical Price Trends
| Year |
Average Wholesale Price (AWP) |
Approximate Net Price |
| 2019 |
$470 |
$330 |
| 2020 |
$455 |
$320 |
| 2021 |
$460 |
$330 |
| 2022 |
$455 |
$330 |
Prices remained relatively stable since launch, with mild reductions reflecting increased competition.
Price Forecast (2023–2027)
Projected trends indicate modest price stability with slight declines due to increased market competition and potential formation of biosimilar-like generics or improved formulations. Expected average net prices per 30-count tablet:
| Year |
Expected Net Price (Est.) |
| 2023 |
$330 |
| 2024 |
$325 |
| 2025 |
$320 |
| 2026 |
$315 |
| 2027 |
$310 |
The decline rate approximates 1–2% annually, driven by competitive market dynamics and payer negotiations.
Market Drivers and Risks
Key Drivers
- Aging population increases demand for effective sleep therapies.
- Favorable safety profile encourages prescriber adoption.
- Growth in insomnia prevalence linked to conditions such as anxiety and depression.
Risks
- Competition from generics or similar MOA drugs.
- Market saturation of current treatments.
- Regulatory or formulary restrictions.
Strategic Considerations
Pharmaceutical companies may focus on expanding indications, such as shift work disorder or comorbid conditions, to sustain revenue growth. Pricing strategies will likely lean toward volume-based approaches amid pricing pressures.
Summary
Lemborexant’s market is growing modestly, driven by population aging and awareness of its safety benefits. Current pricing remains stable, with gradual declines expected through 2027. The drug competes in a saturated sleeping aids market, though its differentiated profile supports continued adoption.
Key Takeaways
- Estimated 2023 sales: $340 million.
- Market share: 10%, growing with expanded indication and prescriber experience.
- Pricing: Stable around $330 net per 30 pills, declining slightly each year.
- Competition from older drugs and potential generics bounds pricing power.
- Future growth relies on expanding indications and formulary inclusion.
FAQs
1. How does Lemborexant compare to other insomnia drugs in pricing?
It is priced at a slight premium over older drugs like zolpidem but remains competitive due to its safety profile.
2. What factors could significantly impact Lemborexant’s market?
Entry of generics, new formulations, or alternative therapies that demonstrate superior efficacy or safety.
3. How long will the patent protection last?
Patent protection generally extends into the mid-2030s, with exclusivity ending around 2036–2037.
4. Are there any upcoming regulatory changes affecting pricing?
Changes involving drug rebate policies and price transparency regulations could pressure net prices.
5. Is Lemborexant’s market growth expected to accelerate or slow?
Growth will likely slow as it approaches market saturation, unless new indications or formulations are introduced.
References
[1] IQVIA, "2022 Prescription Drug Market Reports," 2023.
[2] FDA, "Approval Package: Dayvigo (Lemborexant)," 2019.
[3] MarketWatch, "Insomnia Drug Market Analysis," 2023.
